Triple combination creams (hydroquinone 4%, tretinoin 0.05%, fluocinolone 0.01% in branded Tri-Luma) target melasma through three simultaneous mechanisms: tyrosinase inhibition (hydroquinone), accelerated turnover (tretinoin), and inflammation control (fluocinolone). Compounded versions follow the same pharmacologic logic for refractory hyperpigmentation.
Hydroquinone blocks melanin synthesis; results appear over 8 to 12 weeks. Tretinoin drives pigment dispersion; fluocinolone reduces the inflammation that triggers post-inflammatory hyperpigmentation, especially in darker skin phototypes.
Safety and duration
Use for limited cycles (typically 3 to 5 months) under supervision. Prolonged unsupervised hydroquinone risks exogenous ochronosis. Strict SPF 50+ daily is non-negotiable; UV re-triggers melasma faster than cream fades it.
CLYR Health offers hydroquinone triple cream as a preview skin SKU for provider-supervised hyperpigmentation protocols.